Rice Partnership LLC decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 14.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,234 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Rice Partnership LLC’s holdings in Bristol-Myers Squibb were worth $488,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of BMY. Capital Financial Planning LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Financial Gravity Wealth Inc. bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $26,000. Well Done LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $30,000. Riverview Trust Co bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $33,000. Finally, Trust Department MB Financial Bank N A bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 77.65% of the company’s stock.
Shares of BMY stock opened at $47.63 on Thursday. The stock has a market capitalization of $76.67 billion, a PE ratio of 11.97, a PEG ratio of 2.19 and a beta of 0.74. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69.
In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were acquired at an average price of $47.29 per share, with a total value of $236,450.00. Following the transaction, the director now directly owns 27,000 shares of the company’s stock, valued at $1,276,830. The disclosure for this purchase can be found here. Corporate insiders own 0.12% of the company’s stock.
Several research analysts recently issued reports on BMY shares. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. Goldman Sachs Group started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, May 28th. They set a “buy” rating and a $54.00 target price on the stock. Finally, Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price on the stock. in a research note on Monday, May 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $56.69.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Investing strategies using the yield curve
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.